This invention is an improved method of robust and scalable production of precursors of active cannabinoids, including geranyl pyrophosphate (GPP) and/or cannabigerolic acid (CBGA), in a methylotrophic yeast host cell. The improved methods incorporate a polypeptide encoding an Erg20 variant (F98W/N128W) into a methylotrophic yeast host cell, for example Pichia pastoris (Komagataella phaffii), that biases the natural production of FPP and GPP towards GPP, a precursor to the intermediate CBGA, crucial to the synthesis of active cannabinoids.

Objects are to provide: a fusion protein capable of binding to lipid droplets while having an enzymatic activity to synthesize a hydrophobic compound; a method for producing a substance including accumulating a hydrophobic compound in lipid droplets using the fusion protein; a vector which can enhance production of a hydrophobic compound when it is introduced into cells using genetic recombination techniques; and a transgenic cell into which the vector or a gene coding for the fusion protein has been introduced. The present disclosure relates to a fusion protein having an amino acid sequence (first amino acid sequence) capable of binding to lipid droplets, and an amino acid sequence (second amino acid sequence) having an enzymatic activity to synthesize a hydrophobic compound, with the enzymatic activity of the second amino acid sequence being maintained.

The present invention relates generally to methods and compositions for gene therapy and immunotherapy that activate gamma delta T-cells, and in particular, can be used in the treatment of various cancers and infectious diseases.

The present disclosure relates to the production of cannabinoids in either recombinant microorganism or in cell-free systems using a combination of enzymes, including but not limited to a PKS enzyme, a npgA enzyme, a cs-OLAS-1, a pp-DVAS-1, a cs-HEX-1 and/or Butiryl synthase.

The invention relates to engineered microorganisms (e.g., E. coli) and associated improvements for increasing the production cannabinoids (e.g. CBGA) or precursors or derivatives thereof.

This invention relates to the field of genetic engineering. Specifically, the invention relates to the construction of operons to produce biologically active agents. For example, operons may be constructed to produce agents that control the function of biochemical pathway proteins (e.g., protein phosphatases, kinases and/or proteases). Such agents may include inhibitors and modulators that may be used in studying or controlling phosphatase function associated with abnormalities in a phosphatase pathway or expression level. Fusion proteins, such as light activated protein phosphatases, may be genetically encoded and expressed as photoswitchable phosphatases. Systems are provided for use in controlling phosphatase function within living cells or in identifying small molecule inhibitors/activator/modulator molecules of protein phosphatases associated with cell signaling.

The present disclosure provides methods and compositions for producing rotundone. In various aspects, the present disclosure provides enzymes, polynucleotides encoding said enzymes, and recombinant microbial host cells (or microbial host strains) for the production of rotundone. In some embodiments, the present disclosure provides microbial host cells for producing rotundone at high purity and/or yield, from either enzymatic transformation of α-guaiene, or from sugar or other carbon source. The present disclosure further provides methods of making products containing rotundone, including flavor or fragrance products, among others.

The present disclosure provides methods and compositions for producing rotundone. In various aspects, the present disclosure provides enzymes, polynucleotides encoding said enzymes, and recombinant microbial host cells (or microbial host strains) for the production of rotundone. In some embodiments, the present disclosure provides microbial host cells for producing rotundone at high purity and/or yield, from either enzymatic transformation of α-guaiene, or from sugar or other carbon source. The present disclosure further provides methods of making products containing rotundone, including flavor or fragrance products, among others.

The present specification discloses a transformed Synechococcus elongatus strain which may directly produce squalene from carbon dioxide, and a method for producing squalene and a method for removing carbon dioxide, using the same. In an aspect, the strain may produce squalene using carbon dioxide as a carbon source. The Synechococcus elongatus strain is economically efficient because a high-value added squalene is produced using light and carbon dioxide present in the atmosphere as a carbon source, and the method for producing squalene is eco-friendly because the strain may be utilized to remove or reduce carbon dioxide in the atmosphere by using microorganisms. The strain of the present disclosure may produce only squalene, which is a desired target material with high purity, and has an advantage in that squalene may be continuously mass-produced.

A composition for treating cancer is disclosed. The composition includes a lentiviral particle and an aminobisphosphonate drug. The lentiviral particle is capable of infecting a target cell, such as a cancer cell, and includes an envelope protein optimized for targeting such target cell and a viral vector. The viral vector includes a small RNA optimized to target an FDPS mRNA sequence. The aminobisphosphonate drug includes zoledronic acid.